View:
1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.3)* IDEC PHARMACEUTICALS CORPORATION - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, No Par Value - -------------------------------------------------------------------------------- (Title of Class of Securities) 004493701 - -------------------------------------------------------------------------------- (CUSIP Number) Donald F. Parman, SmithKline Beecham Corporation One Franklin Plaza, Philadelphia, PA 19102 Telephone 215-751-7633 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 21, 1997 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D CUSIP NO. 857304100 PAGE 2 OF 6 PAGES - -------------------------------------------------------------------------------- This Amendment No. 3 amends and supplements the Statement on Schedule 13D manually filed with the Securities and Exchange Commission (the "Commission") on April 24, 1995 (the "Initial Statement") filed jointly by SmithKline Beecham plc, SmithKline Beecham Corporation, and S.R. One, Limited; Amendment No. 1 electronically filed on September 26, 1996; and Amendment No. 2 electronically filed on December 13, 1996 with respect to ownership of securities of IDEC Pharmaceuticals Corporation. The undersigned hereby amends and supplements Item 5 of the Initial Statement by the following information (capitalized terms used herein without definition shall have the same meaning as set forth in the Initial Statement. 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON SmithKline Beecham plc 98-0101920 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /x/ (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION England - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES -0- BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING None PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER -0- ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER None - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -0- - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- 3 SCHEDULE 13D CUSIP NO. 0004493701 Page 3 of 6 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON SmithKline Beecham Corporation 23-1099050 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /x/ (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Pennsylvania - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 1,105,860 BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING None PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 1,105,860 ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER None - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,105,860 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.1% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- 4 Page 4 of 6 Pages Item 1. Security and Issuer. Item 2. Identity and Background. Item 3. Source and Amount of Funds or Other Consideration. Item 4. Purpose of Transaction. 5 Page 5 of 6 Pages Item 5. Interest in Securities of the Issuer. (a) Amount and Percent Beneficially Owned Registered Name No. of Shares Percent SmithKline Beecham plc -0- 0% SmithKline Beecham Corporation 1,105,860 6.1% _______ TOTAL 6.1% (b) (c) The reporting persons sold 885,000 shares of Common Stock in the open market in the following manner: (d) (e) Item 6. Contracts, Arrangements, Understandings or Relationship With respect to Securities of the Issuer. Item 7. Materials to be Filed as Exhibits.
Registered Name Transaction Date Number of Share Price Per Share SmithKline Beecham plc February 5, 1997 70,000 $22.50 SmithKline Beecham plc February 13, 1997 15,000 $22.25 SmithKline Beecham plc February 14, 1997 7,500 $22.375 SmithKline Beecham plc February 14, 1997 10,000 $22.50 SmithKline Beecham plc February 18, 1997 2,500 $22.375 SmithKline Beecham plc Feburary 20, 1997 2,000 $22.25 SmithKline Beecham plc February 21, 1997 60,000 $22.50 SmithKline Beecham plc February 21, 1997 150,000 $22.575 SmithKline Beecham plc February 21, 1997 100,000 $22.625 SmithKline Beecham plc February 21, 1997 145,000 $22.75 SmithKline Beecham plc February 21, 1997 38,000 $22.875 _______ 600,000 SmithKline Beecham Corporation February 21, 1997 5,000 $23.00 SmithKline Beecham Corporation February 24, 1997 50,000 $23.25 SmithKline Beecham Corporation February 24, 1997 145,000 $23.625 SmithKline Beecham Corporation February 24, 1997 50,000 $24.00 SmithKline Beecham Corporation February 24, 1997 6,000 $24.25 SmithKline Beecham Corporation February 25, 1997 29,000 $24.50 SmithKline Beecham Corporation February 28, 1997 17,500 $24.50 SmithKline Beecham Corporation February 28, 1997 25,000 $24.625 SmithKline Beecham Corporation February 28, 1997 5,000 $24.750 SmithKline Beecham Corporation February 28, 1997 2,500 $24.875 _______ 335,000 6 Page 6 of 6 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in the Statement is true, correct and complete. SMITHKLINE BEECHAM PLC By: /s/Alison M. Horler ------------------------------ Alison M. Horler Deputy Secretary SMITHKLINE BEECHAM CORPORATION By: /s/Donald F. Parman ------------------------------ Donald F. Parman Secretary DATED: March 3, 1997